FDA approves Cardiovascular Systems' catheter trial
This article was originally published in Clinica
Cardiovascular Systems has received a conditional Investigational Device Exemption (IDE) approval from the US FDA to begin a trial of its Diamondback 360° catheter. The catheter, cleared by the FDA in 2007 for the treatment of peripheral arterial disease, will now be tested in the treatment of calcified coronary lesions. A pivotal trial, ORBIT II, will initially enrol up to 100 patients. St Paul, Minnesota-based Cardiovascular Systems estimates the US market for coronary interventions at more than $4bn.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.